Jan Reinhart - Profile and Investment Details

Investor Profile

Jan Reinhart is a Venture Capital, Private Equity Firm based in Switzerland with a diverse investment portfolio that includes companies such as Borean Pharma, Ikaria, Synosia Therapeutics, MerLion Pharma, Symetis, Kalypsys, S*Bio, Omeros, Evolva, Synaffix BV, ImVisioN Therapeutics, Nura, Telormedix, NovImmune, Bird Rock Bio, Athelas, Ambrx, Bellerophon Therapeutics, Miikana Therapeutics, . Over time, Jan Reinhart has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Jan Reinhart is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Wellness, Women Founded, Investment Management, Life Science, Portfolio Management, Startups, Biotechnology, Food and Beverage, Innovation, Consulting, Medical, Therapeutics, Financial Advisory, Pharmaceuticals, Risk Management may find it worthwhile to explore potential connections with Jan Reinhart, as their portfolio suggests a familiarity and interest in this area.

Understanding Jan Reinhart’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.